You are here: Home » Companies » News
Business Standard

Sun Pharma considering buying German drug firm

Bloomberg  |  Paris/Mumbai 

Sun Pharmaceutical Industries Ltd, India’s largest drug maker by market value, is looking for acquisitions in Europe, including a possible takeover of German generic drug maker Stada Arzneimittel AG, people familiar with the matter said.

Sun has sought to raise about $1 billion for a European deal, said one person familiar with the matter, who asked not to be identified as the process was private. Company executives recently toured Europe to meet with potential targets, another person said.

Stada, based in Bad Vilbel, Germany, has a market value of about euro 1.4 billion ($1.7 billion). The company’s shares were down 3.3 per cent to euro 24.73 at 4.02 pm in Frankfurt after falling as much as 7.45 per cent on Thursday after Deutsche Bank AG cut its stock-price prediction to euro 32.5 from euro 34.

Sun fell 0.6 per cent to Rs 656 in Mumbai trading on Thursday, valuing the company at Rs 67,500 crore ($12 billion). The stock has climbed 32 per cent this year, compared with the 12 per cent return on the 17-company BSE India Healthcare Index.

A spokesman for Sun said the company wasn’t in talks to buy Stada. A spokesman for Stada declined to comment on a potential deal.

Sun, controlled by billionaire Dilip Shanghvi, has about $927 million of cash reserves and may seek acquisitions to broaden its geographic breadth or enhance its presence in the US, Nomura Holdings Inc said in a May 31 report.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, August 03 2012. 00:33 IST